BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34105142)

  • 21. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Hellmich B; Holl-Ulrich K; Gross WL
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
    Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.
    Tabata R; Tabata C; Katashima Y; Yasumizu R
    Int Immunopharmacol; 2013 Aug; 16(4):488-91. PubMed ID: 23669338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New insights into hypereosinophilic syndromes].
    Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
    Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
    Requena G; van den Bosch J; Akuthota P; Kovalszki A; Steinfeld J; Kwon N; Van Dyke MK
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2125-2134. PubMed ID: 35470096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
    Nanagas VC; Kovalszki A
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
    Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
    Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
    Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The hypereosinophilic syndromes: current concepts and treatments.
    Gleich GJ; Leiferman KM
    Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
    Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of hypereosinophilic syndrome with cyclosporine.
    Donald CE; Kahn MJ
    Am J Med Sci; 2009 Jan; 337(1):65-6. PubMed ID: 19002011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The hypereosinophilic syndrome].
    Jegou J; Barete S; Frances C
    Ann Dermatol Venereol; 2003; 130(6-7):664-6. PubMed ID: 13679710
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
    Klion A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review.
    Yoon TY; Ahn GB; Chang SH
    J Dermatol; 2000 Feb; 27(2):110-5. PubMed ID: 10721659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.
    Dispenza MC; Bochner BS
    Curr Hematol Malig Rep; 2018 Jun; 13(3):191-201. PubMed ID: 29680938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cough in hypereosinophilic syndrome: case report and literature review.
    Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
    BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.